EP0000520B1 - Improvement in or relating to a process for producing interferon - Google Patents
Improvement in or relating to a process for producing interferon Download PDFInfo
- Publication number
- EP0000520B1 EP0000520B1 EP78100395A EP78100395A EP0000520B1 EP 0000520 B1 EP0000520 B1 EP 0000520B1 EP 78100395 A EP78100395 A EP 78100395A EP 78100395 A EP78100395 A EP 78100395A EP 0000520 B1 EP0000520 B1 EP 0000520B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- cells
- interferon
- medium
- acid
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
Definitions
- This invention relates to improvements in or relating to a process for producing the substances called interferons, which have non-specific antiviral effects.
- An interferon is an antiviral proteinaceous substance which is produced by a cell in response to stimulation by a virus or other inducing agent.
- Inferferons can be produced by most cells, for example white blood cells, fibroblasts, lymphoblastoid cells, cells of epithelial types such as kidney cells or HeLa cells, myeloma cells, etc.
- the particular cells chosen to produce interferon will depend on the product required, since interferons have characteristics depending on the host from which they are derived. If interferon is required for use in man, human cells are the preferred source. When formed, an interferon is excreted from the cell, and can then interact with other cells to inhibit virus replication or produce other effects. This antiviral effect is not specific to particular viruses, though some viruses are more sensitive to the effect of interferons than others.
- Interferon has also been used in a chemotherapeutic regime for treatment of certain types of cancers, and appears to have a beneficial effect (Strarider. H., Cantell, K., et al., Fogargty Intern. Center Proc., U.S. Govt. Printing Office, Washington D.C., 28: pp 377-381, 1977 Presented at the Conference at the National Institute of Health, Bethezda, Dec. 9-11, 1974.
- human peripheral blood leukocytes human fibroblasts and human lymphoblastoid cells.
- human peripheral leukocytes production of interferon from human peripheral leukocytes is limited by the availability of human blood.
- Large scale production of interferon from fibroblasts is hampered by the fact that these cells will only grow when adherent to a surface.
- Lymphoblastoid cells have the advantage that they can be grown in large suspension cultures, and can be induced to form interferon by treatment with a virus.
- interferon produced from human lymphoblastoid cells by such methods can vary considerably, for example titres as high as 60-80 mega units (a mega unit equals 10 S units of interferon in terms of the Medical Research Council research standard preparation of interferon, 69/19, see N. Finter, Interferons, 1973, pp. 485-4.86, published by North Holland) of interferon per litre may be obtained, corresponding to yields of 30-40 mega units per 10" cells; on other occasions the titres may be only 1 mega unit or less per litre (or 0.5-0.7 mega units per 10 9 cells) from similar cells induced under apparently identical conditions. The causes of such variations in the yield of interferon are unknown.
- interferon levels may be increased slightly by changing the medium in which the cells are suspended at the time of induction of interferon production.
- a process for producing interferon which comprises adding an interferon inducer to cells which are susceptible to being induced to form interferon characterized in that prior to induction the cells are incubated in a medium containing an amount of a straight chain alkanoic acid, or a salt thereof, effective to enhance interferon production without being toxic to the cells.
- the cells selected for interferon production are chosen according to the requirement, thus if the interferon is for administration to humans, then human cells are the type usually selected.
- the cells used may be epithelial cells, or lymphoblastoid cells such as Namalva cells or other lymphoblastoid cell lines. Lines of lymphoblastoid cells that can be serially propogated in culture are readily derived from cultures of peripheral human blood leukocytes by well established methods (see for example, Hope, J. H., Home, M. K., Scott, W., lnt. J. Cancer, 3, pp 857-866 (1978), Hope, J. H., Horne, M. K. , Scott, W., Int. J.
- the leukocytes may be obtained from normal or diseased individuals, and they may be derived "spontaneously" if the cells are already infected with Epstein-Barr Virus (EBV), or they may be derived from cultures of leukocytes that are not infected with EBV, e.g. umbilical cord blood leukocytes, to which EBV of infectious mononucleosis or Burkitt lymphoma origins have been added.
- EBV Epstein-Barr Virus
- Lymphoblastoid cell lines are readily derived from the cells of patients with Burkitt's lymphoma as these are already infected with EBV.
- One particular line of Namalva was derived in Sweden by Prof. G. Klein (Nyornoi, 0., Klein G., Adams, A., Dombon, L., Int. J. Cancer, 12, pp 396-408 (1973)) from cells obtained from an African female child of that name. Cells of this line have been found to produce large amounts of interferon when suitably stimulated (Strander, H., Morgensen, K. E., Cantell, K., J. Clin. Micro., 1, pp 116-117, (1975)). The subculture of this cell line was obtained from Dr.
- Ion Gresser (Villejuif, France) in January 1975. At that time the line was adapted to grow on medium RMPI 1640 with 10% foetal calf serum. In these laboratories the cells have been adapted to grow on the same medium supplemented with 5-7% serum derived from 6-8 month old calves and they have been subcultured two or three times a week during an 18 month period. A stock of these cells now termed Namalva/WRL has been laid down in a number of ampoules which are stored in liquid nitogen. These cells have been shown to be free from mycoplasma infections and samples have been deposited with the American Type Culture Collection. *
- Namalva/WRL cells were used in the examples described hereinafter but the invention also has been applied to other sub-lines of Namalva cells and other lymphoblastoid cells.
- the straight chain alkanoic acid used in the medium preferably has from 2 to 8 carbon atoms, more preferably 3 to 6 carbon atoms, and most preferably it is butyric acid. If the acid itself is used, then on addition to the medium, which will contain various inorganic or organic salts, the salt of the acid is usually formed. Alternatively, it is possible to add the salt of the carboxylic acid to the medium in which case such salts as the sodium, potassium or ammonium salt may be used.
- human lymphoblastoid cells such as the Namalva cell line
- a growth medium such as RPMI 1640 (Moore, G. E., et. al., 1967, J. Amer. Med. Assoc. 199, 519-524) supplemented with serum, for example calf or horse serum, usually at 5%-10% (v/v).
- the cells are grown in suspension until they have reached an adequate concentration, for example from 0.5 to 10 x 10 s cells/ml after which they can be conveniently processed for interferon production.
- the cell concentration is adjusted to between 0.25 to 6 x 10 B cells/ml, preferably 0.5 to 3 x 10 8 cells/ml, most preferably 1 x 10 6 cells/ml in a medium which can be one of the following: (a) fresh growth medium, (b) the spent growth medium in which the cells were previously grown, supplemented with fresh growth medium, or (c) the spent medium supplemented with fresh nutrients.
- the carboxylic acid or salt thereof may be added to the cell culture to give a final concentration of 0.1 to 10mM, preferably 0.2 to 5mM, most preferably 0.5 to 2.0mM.
- concentration is limited by the toxicity of the carboxylic acid for the cells but should be present in an amount so as to be effective in the enhancement of interferon production, and so the optimum balance between improved interferon yield and cell toxicity must be determined for the acid selected for use.
- carboxylic acids other than butyric acid different molarities may be preferable.
- the cells After incubation the cells are then separated from the medium containing the carboxylic acid by some suitable method which does not damage them, for example centrifugation or filtration.
- the cells may according to the known art (Tovey M. G., et. al. Proc. of Soc. for Exp. Biol. et Med., 146, 809-815 (1974)) then be resuspended in a suitable medium, and induced to form interferon.
- they may be resuspended in medium RPM1 1640, containing no serum or supplemented with up to 5% v/v serum, to give a final cell concentration of from 0.25 to 8 x 10 8 cells/ml, preferably 0.5 to 4 x 10 6 cells/ml.
- a suitable inducer such as a virus, for example Sendai virus, is added to the cell suspension to give a final concentration of 5 to 200 HAU/ml, preferably 20 to 50 HAU/ml.
- a virus for example Sendai virus
- the cell suspension is incubated for a period of 12 to 48 hours at a temperature of from 34 to 37°C.
- the cell culture can conveniently be incubated overnight, during which time interferon is liberated from the cells into the medium.
- the cells are removed by for example centrifugation, leaving a supernatant containing the crude interferon.
- the advantage of incubating the cells in the presence of a straight chain alkanoic acid or salt thereof, before inducing them to form interferon is that relatively high yields of interferon are produced, that is 5-50 mega units per litre or higher, more consistently than in the absence of the treatment.
- cells that have been adapted to grow in a medium containing a low serum supplement, e.g. 1 to 2% v/v will produce as much interferon as cells growing in medium supplemented with three to four times the amount of serum. This feature is of considerable importance since the cost of the serum comprises a large part of the cost of producing the interferon.
- a further advantage of incubating the cells in the presence of a carboxylic acid is that the step of priming the cells with a small amount of homologous interferon becomes redundant, resulting in a saving in production costs.
- Human lymphoblastoid cells of the Namalva/WRL line were grown in suspension in a mechanically stirred 100 litre vessel in a growth medium consisting of medium RMPI 1640 supplemented with 7% calf serum, neomycin and polymyxin, and with bicarbonate for pH control.
- medium RMPI 1640 supplemented with 7% calf serum, neomycin and polymyxin, and with bicarbonate for pH control.
- 10 litres were withdrawn from the vessel and diluted with an equivalent volume of fresh growth medium.
- Butyric acid was added to give a final concentration of 1 mM, and the cells were incubated at 37°C for 48 hours. During this period, the cells were stirred in glass flasks, and the ratio between the volume of cell suspension and the overlying air was approximately 2:5.
- the cells were centrifuged at 2,500 r.p.m. for 5 minutes at 20°C in a MSE Coolspin centrifuge.
- the cell pellet was resuspended in medium RMPI 1640 containing 2% calf serum, and the cell concentration was estimated.
- the cells were diluted to a final concentration of 2.75 x 10 S cells per ml, and to prime them, pre-formed lymphoblastoid interferon was added to give a final concentration of approximately 100 reference interferon units per ml.
- Sendai virus was then added to a final concentration of 75 haemagglutination units per mi. to induce the interferon formation.
- the cell suspension was put into Thompson bottles (300 ml per bottle), which were incubated at 35°C overnight. On the following day, the cell suspensions were centrifuged at 3,000 r.p.m. for 10 minutes at 4°C in a Coolspin centrifuge. The supernatant fluid, containing the crude interferon, was acidified for 24 hours at pH 2, and then neutralised to pH 4 for subsequent storage.
- Namalva/WRL cells were grown to a concentration of 2.5 x 10 * cells/ml in the medium used in Example 1 and were collected by centifugation at 800 x g for 10 minutes; the cell pellet was resuspended in fresh growth medium.
- the cell suspension was diluted to a final concentration of 1.3 x 10 * cells/ml, and 50 ml samples were dispensed into 75 cm 2 plastic tissue culture flasks. Different amounts of a 100mM solution of sodium butyrate in phosphate buffered saline were then added to individual flasks to give a final concentration of sodium butyrate of 0, 0.1, 0.2, 0.5, 1,2 and 5 mM.
- the flasks were incubated at 36°C for 48 hours, and then the cells in each flask were: concentrated by centrifugation at 800 x g for 5 minutes. Each cell pellet was resuspended to a final, concentration of 4.3 x 10 * cells/ml in RMPI 1640 medium containing 2% (v/v) calf serum (maintenance medium). Samples of 10 ml of each cell suspension were placed in two 25 cm 2 plastic tissue culture flasks, which were induced to form interferon by the addition of Sendai virus to give a final concentration of 40 HAU/ml.
- the flasks were returned to 36°C for 20 hours.
- the interferon produced by each culture was harvested by sedimenting the cells at 1,000 x g for 5 minutes.
- the supernatant containing the interferon was adjusted to pH 2.0 by the addition of concentrated hydrochloric acid and stored at 4°C overnight. On the following day, the pH was adjusted to 7.0, and each sample was assayed for its interferon content.
- Example 2 The method of preparing interferon as described in Example 2 was followed except that the sodium butyrate was replaced by sodium acetate, and the concentrations used were 0, 0.2, 1.0, 5.0 mM. The results were as follows
- the cells in the flask which received no sodium butyrate and in one of the flasks which received 1 mM sodium butyrate were sedimented from the medium at 1000 x g for 5 minutes, resuspended in RPMI 1640 medium containing 2% v/v calf serum and adjusted to 3.0 x 10 6 cells/ml. They were induced to synthesize interferon by addition of Sendai virus to a final concentration of 20 HAU/ml.
- the cells in the remaining flasks were pooled, centrifuged at 1000 x g for 5 minutes and resuspended to a concentration of 1.0 x 10 8 cells/ml in fresh RPMI 1640 growth medium containing no sodium butyrate.
- Plastic tissue culture flasks having a surface area of 25 cm 2 available for cell growth were seeded with V3 cells, Christofinis G. J., J. Med. Micro, 3(2), 251 ⁇ 258, 1970, at 1.5 x 10 5 cells/ml in 10 ml of Eagles Basal medium containing 4% v/v of foetal calf serum.
- the flasks were placed at 36°C for 24 hours to allow the cells to attach to the plastic and establish.
- the growth medium was removed from each flask and the cells re-fed with 10 ml of fresh growth medium.
- sodium butyrate in phosphate buffered saline was added to a final concentration of 2mM.
- Namalva/WRL cells were sedimented from spent growth medium and resuspended in fresh RPMI 1640 medium containing 7% v/v calf serum to a concentration of 1.38 x 10 8 cells/ml. 500 ml were placed in each of two 1 litre glass jars, and to one culture sodium butyrate in phosphate buffered saline was added to a final concentration of 1 mM. The cultures were stirred at 36° for 48 hours. The cells were recovered by centrifugation and resuspended in RPMI 1640 medium containing 2% v/v calf serum to a concentration of 5.0 x 10 6 cells/ml. Aliquots of 10 ml of these cell preparations were induced with the agents tested. The supernatants from the virus-induced cultures were processed as usual at pH 2 before being assayed for their interferon content. The results were as follows:-
- Polyribosinic acid - polyribocytidylic acid complex was obtained from P-L Biochemicals Inc. Lot No. 447121.
- Namalva/WRL cells which normally grow in medium RPMI 1640 containing 7% calf serum, were adapted to grow in medium containing only 2% calf serum. These cultures regularly yielded cell counts of 1.5-2.0 x 10 6 /ml.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB2987177 | 1977-07-15 | ||
GB2987177 | 1977-07-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0000520A1 EP0000520A1 (en) | 1979-02-07 |
EP0000520B1 true EP0000520B1 (en) | 1981-03-25 |
Family
ID=10298554
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP78100395A Expired EP0000520B1 (en) | 1977-07-15 | 1978-07-14 | Improvement in or relating to a process for producing interferon |
Country Status (15)
Country | Link |
---|---|
US (1) | US4216203A (xx) |
EP (1) | EP0000520B1 (xx) |
JP (1) | JPS5420119A (xx) |
AT (1) | AT362334B (xx) |
AU (1) | AU524099B2 (xx) |
CA (1) | CA1115209A (xx) |
CS (1) | CS215108B2 (xx) |
DE (1) | DE2860559D1 (xx) |
DK (1) | DK147625C (xx) |
ES (1) | ES471721A1 (xx) |
FI (1) | FI60971C (xx) |
HU (1) | HU179655B (xx) |
IL (1) | IL55143A0 (xx) |
IT (1) | IT1107573B (xx) |
PL (1) | PL110704B1 (xx) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6962695B1 (en) | 1998-12-29 | 2005-11-08 | Bionative Ab | Modification of interferon alpha production |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0005476B1 (de) * | 1978-05-17 | 1981-12-30 | Dr. Karl Thomae GmbH | Verfahren zur Herstellung von Humaninterferon |
JPS55122717A (en) * | 1979-03-15 | 1980-09-20 | Asai Gerumaniumu Kenkyusho:Kk | Interferon inducer |
DE2946275A1 (de) * | 1979-11-16 | 1981-05-27 | Dr. Karl Thomae Gmbh, 7950 Biberach | Verbessertes verfahren zur herstellung von humaninterferon aus lymphoblastoiden zellen |
JPS56135420A (en) * | 1980-03-26 | 1981-10-22 | Fumiaki Taguchi | Suppressive substance of virus and its preparation |
KR860001471B1 (ko) | 1980-04-03 | 1986-09-26 | 비오겐 엔. 브이 | 인체의 섬유아세포 인터페론(IFN-β)폴리펩티드의 제조방법 |
US4460574A (en) * | 1980-06-16 | 1984-07-17 | Yabrov Alexander A | Prophylaxis or treatment of interferon-sensitive diseases |
JPS5754586A (en) * | 1980-09-18 | 1982-04-01 | Ajinomoto Co Inc | Cell strain producing human interferon prolongably, its preparation, and preparation of human interferon using it |
FR2502009A1 (fr) * | 1981-03-23 | 1982-09-24 | Centre Nat Rech Scient | Perfectionnements aux procedes de fabrication d'interferon |
EP0062085B1 (de) * | 1981-04-07 | 1985-08-14 | Dr. Karl Thomae GmbH | Verbessertes Verfahren zur Herstellung von Humaninterferon aus lymphoblastoiden Zellen |
HU184972B (en) * | 1981-12-01 | 1984-11-28 | Egyt Gyogyszervegyeszeti Gyar | Process for preparing human gamma interferone |
IT1172270B (it) * | 1982-06-21 | 1987-06-18 | Wellcome Found | Procedimento per la produzione di interferon |
US4745053A (en) * | 1983-07-08 | 1988-05-17 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyojo | Process for producing human interferon and method for assaying the interferon productivity of blood |
US4956282A (en) * | 1985-07-29 | 1990-09-11 | Calgene, Inc. | Mammalian peptide expression in plant cells |
US6774283B1 (en) | 1985-07-29 | 2004-08-10 | Calgene Llc | Molecular farming |
DE3930140A1 (de) * | 1989-09-09 | 1991-03-21 | Bayer Ag | Verfahren zur herstellung von biologischen materialien in zellkulturen und vorrichtungen |
US5378612A (en) * | 1990-05-11 | 1995-01-03 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Culture medium for production of recombinant protein |
JPH0775593A (ja) * | 1993-09-08 | 1995-03-20 | Suntory Ltd | 蛋白質の製造方法 |
DE69636112T2 (de) * | 1995-08-30 | 2006-12-14 | Toray Industries, Inc. | Verfahren zum testen von myocarditis und cardiomyopathie |
US6833271B2 (en) * | 1996-12-04 | 2004-12-21 | Medi-Cult A/S | Serum-free cell culture media |
US7294481B1 (en) * | 1999-01-05 | 2007-11-13 | Immunex Corporation | Method for producing recombinant proteins |
GB0208041D0 (en) * | 2002-04-08 | 2002-05-22 | Lonza Biologics Plc | Method of culturing animal cells |
CN112237006B (zh) | 2018-05-31 | 2023-06-30 | 东芝开利株式会社 | 使用触摸面板的设备管理装置及管理画面生成方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2282910A2 (fr) * | 1974-08-26 | 1976-03-26 | Anvar | Procede de fabrication a l'echelle industrielle de preparations d'interferon de titre eleve |
GB1464939A (en) * | 1974-01-11 | 1977-02-16 | Anvar | Process for the production of interferon |
-
1978
- 1978-07-11 CS CS784645A patent/CS215108B2/cs unknown
- 1978-07-14 FI FI782249A patent/FI60971C/fi not_active IP Right Cessation
- 1978-07-14 US US05/924,703 patent/US4216203A/en not_active Expired - Lifetime
- 1978-07-14 CA CA307,456A patent/CA1115209A/en not_active Expired
- 1978-07-14 HU HU78WE579A patent/HU179655B/hu not_active IP Right Cessation
- 1978-07-14 PL PL1978208407A patent/PL110704B1/pl unknown
- 1978-07-14 IL IL55143A patent/IL55143A0/xx not_active IP Right Cessation
- 1978-07-14 AT AT510378A patent/AT362334B/de not_active IP Right Cessation
- 1978-07-14 DK DK316978A patent/DK147625C/da not_active IP Right Cessation
- 1978-07-14 ES ES471721A patent/ES471721A1/es not_active Expired
- 1978-07-14 IT IT50322/78A patent/IT1107573B/it active Protection Beyond IP Right Term
- 1978-07-14 AU AU38049/78A patent/AU524099B2/en not_active Expired
- 1978-07-14 JP JP8599878A patent/JPS5420119A/ja active Granted
- 1978-07-14 EP EP78100395A patent/EP0000520B1/en not_active Expired
- 1978-07-14 DE DE7878100395T patent/DE2860559D1/de not_active Expired
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6962695B1 (en) | 1998-12-29 | 2005-11-08 | Bionative Ab | Modification of interferon alpha production |
Also Published As
Publication number | Publication date |
---|---|
DK147625C (da) | 1985-04-29 |
DK147625B (da) | 1984-10-22 |
HU179655B (en) | 1982-11-29 |
AU524099B2 (en) | 1982-09-02 |
AU3804978A (en) | 1980-01-17 |
FI782249A (fi) | 1979-01-16 |
JPS5646797B2 (xx) | 1981-11-05 |
CS215108B2 (en) | 1982-07-30 |
PL208407A1 (pl) | 1979-03-12 |
IT7850322A0 (it) | 1978-07-14 |
US4216203A (en) | 1980-08-05 |
IL55143A0 (en) | 1978-09-29 |
ES471721A1 (es) | 1979-02-01 |
DE2860559D1 (en) | 1981-04-16 |
FI60971B (fi) | 1982-01-29 |
ATA510378A (de) | 1980-10-15 |
CA1115209A (en) | 1981-12-29 |
AT362334B (de) | 1981-05-11 |
JPS5420119A (en) | 1979-02-15 |
IT1107573B (it) | 1985-11-25 |
PL110704B1 (en) | 1980-07-31 |
DK316978A (da) | 1979-01-16 |
FI60971C (fi) | 1982-05-10 |
EP0000520A1 (en) | 1979-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0000520B1 (en) | Improvement in or relating to a process for producing interferon | |
Langford et al. | Biological effects of staphylococcal enterotoxin A on human peripheral lymphocytes | |
US4357422A (en) | Method of enhancing interferon production | |
Wittmann et al. | Cell-mediated immunity in Aujeszky disease virus infected pigs: I. Lymphocyte stimulation | |
US3800035A (en) | Production of interferon from human leukocytes in the absence of serum | |
Hicks et al. | Adrenal cortical hormones and the formation of histamine and 5-hydroxytryptamine | |
US4296025A (en) | Process for preparing human interferon | |
EP0097353B1 (en) | Improved process for interferon production | |
US4469790A (en) | Continuous and spontaneous interferon producing lymphoblastoid cell lines, process for preparing the same, and process for the human interferon production by the same | |
GB2163750A (en) | Method for producing human leukocyte interferon alpha-2 | |
EP0014050A2 (en) | Interferon production | |
GB2121053A (en) | Production of interleukin and its analogous immune regulating factors | |
Matsuo et al. | Production and purification of human leukocyte interferon | |
EP0048283B1 (en) | Virus-inhibiting substance and process for preparing the same | |
US4480032A (en) | Natural mixture of Type I and Type II interferons | |
US3629235A (en) | Process for isolating an interferon inducer and the product per se | |
Meager et al. | Interferon production: variation in yields from human cell lines | |
Maehara et al. | Enhanced Production of Virus‐Inhibiting Factor (Interferon) in Human Diploid Cells by Ultraviolet Irradiation and Temperature Shift‐Down after Stimulation with Newcastle Disease Virus | |
EP0945463B1 (en) | Process for the preparation of human leukocyte [alpha] interferon | |
Suzuki et al. | Interferon‐Inducing Activity of Acidic Polysaccharides: I. Induction of Rabbit Serum Interferon by Hansenula Phosphomannans | |
JPS641119B2 (xx) | ||
Byfield et al. | Non-coordinate Synthesis of Division-related m RNA | |
Adolf et al. | The human lymphoma cell line NC-37: An alternative source of human lymphoblastoid interferon | |
GB1579515A (en) | Method of preparing interferon | |
JPS61135598A (ja) | インタ−フエロン−αの製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Designated state(s): BE CH DE FR GB NL SE |
|
17P | Request for examination filed | ||
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Designated state(s): BE CH DE FR GB NL SE |
|
REF | Corresponds to: |
Ref document number: 2860559 Country of ref document: DE Date of ref document: 19810416 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 19920713 Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 19920731 Year of fee payment: 15 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Effective date: 19930715 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: CTFF Free format text: GBCTFFSPC/GB93/040, 930518 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: CTFG Free format text: GBCTFGSPC/GB93/040, 930827, EXPIRES:20010302 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: CTFF Free format text: GBCTFFSPC/GB93/040, 930518 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Effective date: 19940201 |
|
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee | ||
EUG | Se: european patent has lapsed |
Ref document number: 78100395.9 Effective date: 19940210 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 19970707 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 19970709 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 19970718 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 19970730 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 19970828 Year of fee payment: 20 |
|
BE20 | Be: patent expired |
Free format text: 980714 THE *WELLCOME FOUNDATION LTD |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 19980713 Ref country code: CH Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 19980713 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: PE20 Effective date: 19980713 Ref country code: GB Ref legal event code: CTFE Free format text: GBCTFESPC/GB93/040, 19980714, EXPIRES: 20010302 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: SPCE Free format text: GBSPCESPC/GB93/040: 20010302 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |